Department of Neurology, Nimes University Hospital, 30900 Nimes, France.
Neurological Institute, Foundation Casimiro Mondino, 27100 Pavia, Italy.
Toxins (Basel). 2018 Jun 1;10(6):221. doi: 10.3390/toxins10060221.
Refractory chronic migraine is a disabling disorder impacting quality of life. BOTOX (Onabotulinumtoxin A) is approved as a prophylactic treatment of chronic migraine in patients unresponsive to at least three prior preventive treatments. The objective of this study was to determine the prophylactic effect of 145 U XEOMIN (Incobotulinumtoxin A) injected at 31 specific sites in adult patients with refractory chronic migraine. Sixty-one patients (8 men and 53 women, mean age 50) with migraine were recruited, including 20 patients with isolated chronic migraine, 18 patients with chronic migraine associating tension-type headache, 12 patients with migraine associating medication , and 11 patients with episodic disabling migraine. The mean number of injections and duration of treatment per patient was 3.5 (range 2⁻13) and 21 (6⁻68) months, respectively. From baseline to first injection, 44 patients (73%) had >50% reduction in frequency of migraine episodes, 29 patients (48%) showed >50% reduction in number of headache days, and 28 patients (46%) had a >50% reduction in drug intake. Stable response for all three parameters was observed after the last injection. XEOMIN thus seems to represent an effective and sustained prophylactic treatment of chronic migraine.
难治性慢性偏头痛是一种致残性疾病，会影响生活质量。BOTOX（肉毒毒素 A）已被批准用于对至少三种预防性治疗无反应的慢性偏头痛患者的预防性治疗。本研究的目的是确定在难治性慢性偏头痛的成年患者中，于 31 个特定部位注射 145U 的 XEOMIN（Incobotulinumtoxin A）的预防性效果。共招募了 61 名偏头痛患者（8 名男性和 53 名女性，平均年龄 50 岁），包括 20 名孤立性慢性偏头痛患者、18 名慢性偏头痛伴紧张型头痛患者、12 名偏头痛伴药物治疗患者和 11 名发作性致残性偏头痛患者。每位患者的平均注射次数和治疗持续时间分别为 3.5（2⁻13）次和 21（6⁻68）个月。从基线到第一次注射，44 名患者（73%）偏头痛发作频率降低超过 50%，29 名患者（48%）头痛天数减少超过 50%，28 名患者（46%）药物摄入减少超过 50%。末次注射后，所有三个参数均观察到稳定的反应。因此，XEOMIN 似乎是一种有效且持续的慢性偏头痛预防性治疗方法。
